Non-insulin-dependent Diabetes Mellitus Induced by Immune Checkpoint Inhibitor Therapy in an Insulinoma-associated Antigen-2 Autoantibody-positive Patient with Advanced Gastric Cancer

A 70-year-old man with insulinoma-associated antigen-2 autoantibodies developed diabetes mellitus (DM) without ketoacidosis after starting nivolumab to treat advanced gastric cancer. He subsequently exhibited preserved insulin-secretion capacity for over one year. Immune checkpoint inhibitors (ICIs)...

Descripción completa

Detalles Bibliográficos
Autores principales: Ohara, Nobumasa, Kobayashi, Michi, Ikeda, Yohei, Hoshi, Takahiro, Morita, Shinichi, Kanefuji, Tsutomu, Yagi, Kazuyoshi, Suda, Takeshi, Takada, Toshinori, Hasegawa, Go, Sato, Yo, Hirano, Kenichiro, Kosugi, Shin-ichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7056377/
https://www.ncbi.nlm.nih.gov/pubmed/31708539
http://dx.doi.org/10.2169/internalmedicine.3208-19
Descripción
Sumario:A 70-year-old man with insulinoma-associated antigen-2 autoantibodies developed diabetes mellitus (DM) without ketoacidosis after starting nivolumab to treat advanced gastric cancer. He subsequently exhibited preserved insulin-secretion capacity for over one year. Immune checkpoint inhibitors (ICIs) infrequently cause type 1 DM associated with the rapid loss of insulin secretion and ketoacidosis as an immune-related adverse event. ICIs may also cause non-insulin-dependent DM by inducing insulin resistance if there is islet autoantibody-related latent beta-cell dysfunction. The present case highlights the importance of testing blood glucose levels regularly to diagnose DM in patients treated with ICIs, even if they do not have diabetic ketoacidosis.

Ejemplares similares